Brief: Eagle Pharmaceuticals Q2 Revenue USD 64.6 Million
08/08/2023 11:51
Aug 08 (Reuters) - Eagle Pharmaceuticals Q2 adjusted net income USD 15.5 million. * Q2 net income USD 5.2 million * outlook FY adjusted EBITDA USD 78-84 million * outlook FY adjusted EPS USD 4.4-4.7
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq